This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Interactions

Authoring team

  • another DMARD - leflunomide should not be concomitantly administered with another DMARD

  • alcohol - this is because of the potential for additive hepatic side effects - therefore alcohol should be avoided whilst on treatment with leflunomide (1)

  • the manufacturer advises caution when concomitantly prescribed with drugs that are metabolised by the cytochrome P4502C (e.g. tolbutamide, warfarin, phenytoin)

  • a live vaccine should not be administered if a patient is currently, or has recently received, treatment with leflunomide

Check manufacturer's information for latest prescribing information.

Reference:

  • 1) Drug and Therapeutics Bulletin (2000), 38 (7), 52-4.

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.